Mr. Wolff was most recently Executive Vice President and Chief Financial Officer of Sangamo Therapeutics, serving at the company from December 2007 until his retirement in March 2017. Prior to joining Sangamo, he was Senior Vice President, Finance and Chief Financial Officer at Nuvelo. Before his work at Nuvelo, Ward was Chief Financial Officer and Senior Vice President, Finance, at Abgenix, Inc. until April 2006 when Abgenix merged with Amgen Inc. Prior to joining Abgenix, Mr. Wolff held financial management positions in both public and private emerging growth companies, including serving as SVP and CFO of DoubleTwist, a life sciences company integrating genomic information and bioinformatics analysis tools. He began his career with Pricewaterhouse, where he held a number of positions as a certified public accountant, including senior audit manager. Mr. Wolff is a member of the board of directors of Portola Pharmaceuticals and Sunesis Pharmaceuticals. He received a B.A. degree in Economics from the University of California at Berkeley, and an M.B.A. degree from Harvard Business School.
Financial Expert